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Background: Ventricular conduction blocks (VCBs) are associated with poor outcomes in patients with known
cardiac diseases. However, the prognostic implications of VCB patterns in dilated cardiomyopathy (DCM) patients
need to be evaluated. The purpose of this study was to determine all-cause mortality in patients with DCM and
VCB.
Methods: This cohort study included 1119 DCM patients with a median follow-up of 34.3 (19.5–60.8) months,
patients were then divided into left bundle branch block (LBBB), right bundle branch block (RBBB), intraventricular
conduction delays (IVCD) and narrow QRS groups. The all-cause mortality was assessed using Kaplan-Meier survival
curves and Cox regression.
Results: Of those 1119 patients, the all-cause mortality rates were highest in patients with IVCD (47.8, n = 32),
intermediate in those with RBBB (32.9, n = 27) and LBBB (27.1 %, n = 60), and lowest in those with narrow QRS
(19.9 %, n = 149). The all-cause mortality risk was significantly different between the VCB and narrow QRS group
(log-rank χ2 = 51.564, P < 0.001). The presence of RBBB, IVCD, PASP ≥ 40 mmHg, left atrium diameter and NYHA
functional class were independent predictors of all-cause mortality in DCM patients.
Conclusions: Our findings indicate that RBBB and IVCD at admission,but not LBBB, were independent
predictors of all-cause mortality in patients with DCM.
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Dilated cardiomyopathy (DCM), a leading cause of heart
failure and arrhythmia, is a disease of the heart muscle
characterized by ventricular dilation and impaired sys-
tolic function. The prognosis in patients with DCM is
poor. However, the clinical spectrum is wide, and it is* Correspondence: lixiaoping0119@163.com; drhua@aliyun.com
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an individual patient may follow.
Patients with DCM present with an increase in the
QRS duration in the presence of a ventricular conduc-
tion block (VCB) [1–3]. There is controversy regard-
ing the type of bundle branch block (BBB) that is
associated with poorer outcomes in patients with heart
failure (HF) [4–8]. Most studies indicate that left BBB
(LBBB) is an independent prognostic marker, whereas
right BBB (RBBB) is a weaker marker or not associated
with a worse prognosis. Conversely, two studies re-
cently showed that RBBB but not LBBB is associated
with an increased 1-year and 4-year mortality risk in
hospitalized patients with HF [9, 10]. Patients withle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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present with DCM, often without specifying the par-
ticular type of BBB. These patients also have worse
clinical outcomes [1–3].
The prognostic implications of VCB in the long-term
mortality of patients with DCM merit examination due to
the lack of data on this issue. Therefore, in the present
study, we evaluated the association of VCB patterns and
all-cause mortality and compared the prognostic values of
RBBB, LBBB, and IVCD in hospitalized patients with
DCM.Fig. 1 An example figure of narrow QRS, LBBB, RBBB, and IVCDSubjects and methods
Patients and follow-up
This study was a retrospective, observational cohort study
of patients with DCM observed from November 2003 to
September 2011. VCB (LBBB, RBBB, IVCD) were identi-
fied from records of individual 12-lead ECGs in 1317
patients (Fig. 1). The patients were admitted due to their
decompensation symptoms and the physical signs of heart
failure, and DCM was defined as systolic dysfunction with
LV dilation in the absence of an apparent secondary cause
of cardiomyopathy [11]. We measured the following DCM
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100 mmHg), coronary artery disease (>50 % in one or
more major branches), chronic excess alcohol consump-
tion (>40 g/day for females, > 80 g/day for males for more
than five years after 6 months of abstinence), systemic
diseases known to cause IDC, pericardial diseases, congeni-
tal heart disease, cor pulmonale, and rapid, sustained sup-
raventricular tachycardia. Of the 1317 enrolled patients, 23
patients with missing electrocardiograph test results and
175 patients with various secondary cardiomyopathies were
excluded from the study. The secondary cardiomyopathies
included the following: 80 patients with ischemic heart
disease by coronary angiography; 26 patients with overt
hyper- and hypothyroidism thyroid disease; 24 patients
with alcohol-induced cardiomyopathy; 16 patients with
congenital heart disease; 16 patients with left ventricle non-
compaction; 7 patients with chronic anemia (hemoglobin
<60 g/L); 2 patients with peripartum cardiomyopathy; and
4 patients with rheumatic heart disease or systemic im-
mune disease (Fig. 2). Thus, the final analysis included
1119 patients. The primary end point of the study was all-
cause mortality, which was assessed for all patients through
their medical records (patient’s hospital records, periodic-
ally examining the patient in the outpatient clinic) and
medical follow-up calls with trained personnel. Data from
patients who underwent cardiac transplantation were cen-
sored at the time of transplantation. The median follow-up
period was 34.3 (19.5–60.8) months, and the study proto-
col was approved by the Ethics Commission of Fuwai
Hospital.Fig. 2 Derivation of the study cohortEchocardiography
The patients were imaged in the left lateral decubitus
position using a commercially available system equipped
with a 3.5 MHz transducer. Two-dimensional gray-scale,
pulsed, continuous, color Doppler data were acquired
from the parasternal and apical views. The left ventricu-
lar ejection fraction (LVEF) was calculated using the bi-
plane Simpson’s technique.
Because pulmonary artery systolic pressure (PASP) is
equal to the right ventricular systolic pressure in the ab-
sence of pulmonary stenosis, PASP was estimated using
Doppler echocardiography by calculating the right ven-
tricular to right atrial pressure gradient during systole
(approximated by the modified Bernoulli equation as
4v2, where v is the velocity of the tricuspid regurgitation
jet in m/s). Right atrial pressure, estimated based on the
echocardiographic characteristics of the inferior vena
cava and assigned a standardized value, was then added
to the calculated gradient to give PASP. According to
the new guideline, presence of PASP ≥ 40 mmHg was
likely to be pulmonary hypertension (PH) [14].
Statistical analyses
Continuous variables are expressed as the means ± SDs or
medians and interquartile ranges. The categorical vari-
ables among groups were compared using chi-square (χ2)
tests. Analysis of variance was used to compare continu-
ous variables among multiple groups. Hazard ratios with
95 % confidence intervals were used to estimate the ad-
justed relative risk of the VCB groups. The Kaplan-Meier
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Multivariate Cox proportional hazards regression models
were used to adjust for any confounding variables among
groups. First, the potential variables were evaluated by
univariate analysis and were then selected based on their
clinical and statistical significance. Second, a multivariate
analysis was performed using Cox proportional hazards
regression modelling adjusted for baseline variables. SPSS
version 16.0 software (SPSS, Chicago, Illinois) was used
for all statistical analyses. All of the tests were two-sided,
and a p value < 0.05 was used to determine statistical
significance.
Results
Characteristics of the study population
The cohort consisted of 1119 patients with DCM: 298
(26.6) women and 821 (73.4) men; 1076 (96.2) were from
the Han population and 43 (3.8 %) were from other races:
the mean age was 51.1 ± 14.7 years. Of those, 19.8 (n = 221)
had LBBB, 7.3 (n = 82) had RBBB, 6.0 (n = 67) had IVCD,
and 66.9 % (n = 749) had narrow QRS. Table 1 summarizes
the baseline clinical characteristics of the cohort. Among
the patients with VCBs (LBBB, RBBB and IVCD) and nar-
row QRS, the number of women with RBBB was lower, and
there was a lower frequency of a history of hypertension
but a greater frequency of PASP ≥ 40 mmHg in patients
with RBBB. Patients with LBBB were older, were predomin-
antly male, had more frequent essential hypertension and
had longer QRS durations, QT intervals and larger LV
diameters. The patients with IVCD had higher levels of
circulating bilirubin, larger left atriums (LAs), larger right
ventricle (RV) diameters, longer PR intervals, and less use
of beta blockers, aspirin and spironolactone during
admission.
Relation between VCB patterns and all-cause mortality
Among the 1119 patients studied, 268 died and 3 under-
went heart transplantation during a median follow-up of
34.3 (19.5–60.8) months. The all-cause mortality rates
were highest in patients with IVCD (47.8 %, n = 32);
intermediate in patients with RBBB (32.9, n = 27) and
LBBB (27.1 %, n = 60); and lowest in patients with nar-
row QRS (19.9 %, n = 149). Over the median of
34.3 month follow-up, there was a significant difference
in all-cause mortality risk between the VCB and narrow
QRS groups (log-rank χ2 = 51.564, P < 0.001) (Fig. 3).
Cox proportional hazard models
Table 2 summarizes the results of the Cox models in
which each of the parameters were entered separately as
the mortality explanatory variable. The univariate ana-
lysis indicated that age, history of essential hypertension
and atrial fibrillation (AF), NYHA functional classes, dis-
ease duration, systolic blood pressure, diastolic bloodpressure, LV, LA diameters, LVEF, PASP ≥ 40 mmHg,
and the presence of LBBB, RBBB and IVCD were predic-
tors of all-cause mortality in DCM patients. After adjust-
ments for age, gender, history of essential hypertension
and AF, smoking and drinking status, disease duration,
blood pressure, heart rate, LV diameter and LVEF value,
using either forward or backward selection, and the
presence of RBBB, IVCD, PASP ≥ 40 mmHg, the NYHA
functional class and LA diameter were the only variables
that remained in the model and emerged as important
predictors. However, unlike RBBB and IVCD, LBBB was
not a predictor of death using the multivariate analysis.
Discussion
In this study, we investigated the associations among dif-
ferent patterns of VCB and all-cause mortality in patients
with DCM. Our major new finding suggests that RBBB
and IVCD upon admission, but not LBBB, were strong
predictors of all-cause mortality in patients with DCM.
Several studies investigating the predictive value of
QRS morphology in patients with HF yielded conflicting
results regarding mortality risk associated with the BBB
pattern [4–7]. Baldasseroni et al. [5, 6] reported that
complete LBBB, but not RBBB, was associated with a
higher adjusted 1-year mortality rate in 5,517 outpatients
with HF. McCullough et al. [4] found higher 2-year mor-
tality rates for RBBB and LBBB compared with patients
with normal QRS, but a multivariate analysis demon-
strated that RBBB was not as powerful a predictor of
mortality as LBBB. Most recently, Mueller et al. [7] ana-
lyzed the impact of the BBB pattern on long-term mor-
tality and found that the mortality was significantly
higher in HF patients with RBBB. Two studies recently
showed that RBBB, but not LBBB, is associated with in-
creased mortality risk in HF patients [9, 10]. None of
these studies, however, reported the relationship be-
tween RBBB and mortality risk in the patients with
DCM. In the present study, we found that RBBB and
IVCD patients with DCM had a higher all-cause mortal-
ity than patients with LBBB, and patients with any pat-
tern of VCB had higher all-cause mortality rates than
patients with a narrow QRS. A multivariate analysis
demonstrated that RBBB and IVCD, but not LBBB, were
the predictors of all-cause mortality in patients with
DCM.
Approximately 30% of patients with heart failure or
cardiomyopathy have VCBs, such as left or right bundle-
branch blocks [5, 9]. Some studies have shown that in
patients with HF, the prevalence of LBBB is higher than
in patients with RBBB [4, 5, 7]. LBBB is associated with
more severe HF characterized by an advanced NYHA
functional class and decreased LVEF, whereas RBBB is
more prevalent in men and is not associated with ad-
vanced HF symptoms or ventricular dysfunction [5, 6].
Table 1 Patient characteristics categorized by ventricular conduction block patterns
All patients (n = 1119) LBBB (n = 221) RBBB (n = 82) IVCD (n = 67) Narrow QRS (n = 749) P value
Age (years) 51.1 ± 14.7 57.2 ± 12.0 53.1 ± 14.7 52.3 ± 14.5 48.9 ± 14.9 <0.001a
Female gender, n (%) 298(26.6) 89(40.3) 16(19.5) 15(22.4) 178(23.8) <0.001
History
Disease duration (years) 2(0.5–6) 4(1–9) 4(1–8) 3(1.5–6) 2(0.35–5) 0.001
Essential hypertension, n (%) 294(26.3) 73(33.0) 15(18.3) 15(22.4) 191(25.5) 0.034
Diabetes mellitus, n (%) 160(14.3) 24(10.9) 15(18.3) 6(9.0) 115(15.4) 0.142
Atrial fibrillation, n (%) 257(23.0) 29(13.1) 20(24.4) 11(16.4) 197(26.3) <0.001
Smoker, n (%) 517(46.2) 93(42.1) 33(40.2) 31(46.3) 360(48.1) 0.293
Drinker, n (%) 363(32.4) 59(26.7) 28(34.1) 22(32.8) 254(33.9) 0.243
NYHA class III and IVc, n (%) 817(73.0) 162(73.3) 60(73.2) 54(80.6) 541(72.2) 0.532
Admission vital signs
SBP (mm Hg) 113.0 ± 17.7 114.6 ± 17.3 110.2 ± 18.8 111.7 ± 19.8 113.0 ± 17.4 0.242
DBP(mm Hg) 72.5 ± 12.6 71.8 ± 12.4 71.8 ± 11.1 69.3 ± 12.4 73.0 + 12.8 0.099
Heart rate, beat/min 80.9 ± 17.4 78.3 ± 15.9 79.6 ± 15.5 78.6 ± 14.4 82.0 ± 18.2 0.023
Laboratory values at admissionb
TB (mmol/L) 26.2 ± 19.6 24.9 ± 19.1 25.3 ± 16.0 34.8 ± 26.7 26.0 ± 19.3 0.004
DB (mmol/L) 3.7(2.5–6.5) 3.2(2.15–6.05) 3.5(2.7–7.4) 4.9(3.2–9.2) 3.7(2.5–6.485) 0.003
Glucose (mmol/L) 5.62 ± 1.85 5.86 ± 1.94 5.50 ± 1.52 5.34 ± 1.44 5.59 ± 1.89 0.150
Triglyceride (mmol/L) 1.57 ± 1.02 1.63 ± 0.99 1.58 ± 0.94 1.38 ± 0.70 1.56 ± 1.06 0.410
Total cholesterol (mmol/L) 4.61 ± 1.13 4.75 ± 1.12 4.52 ± 0.98 4.39 ± 1.23 4.59 ± 1.14 0.125
Creatinine (μmol/L) 92.8 ± 35.2 91.0 ± 26.4 94.9 ± 25.9 97.9 ± 40.7 92.6 ± 37.8 0.526
BUN (μmol/L) 7.95 ± 3.97 7.88 ± 2.67 8.04 ± 2.69 8.89 ± 4.68 7.88 ± 4.32 0.262
CK-MB (IU/L) 13.5 ± 7.76 13.1 ± 6.77 12.0 ± 6.70 13.7 ± 7.59 13.8 ± 8.14 0.229
NT- Pro- BNP (fmol/mL) 2010.3 ± 1567.5 1998.0 ± 1595.8 2170.5 ± 1679.8 2358.4 ± 1638.4 1962.4 ± 1538.0 0.315
Electrocardiogram data
QRS duration (ms) 119.6 ± 30.9 156.0 ± 24.4 153.3 ± 24.9 137.1 ± 23.1 103.6 ± 18.2 <0.001
QT (ms) 405.7 ± 54.2 434.4 ± 50.6 429.1 ± 51.1 421.3 ± 38.7 393.2 ± 52.4 <0.001
P (ms) 107.5 ± 21.6 102.7 ± 22.6 107.5 ± 23.6 108.2 ± 25.1 109.3 ± 20.3 0.005
PR (ms) 182.8 ± 32.9 184.9 ± 33.1 192.3 ± 42.0 193.6 ± 34.7 179.7 ± 30.7 0.001
Echocardiography data
LV (mm) 68.0 ± 9.3 71.4 ± 11.4 68.7 ± 8.3 70.9 ± 13.1 66.7 ± 8.0 <0.001
LVEF (%) 31.9 ± 8.4 31.0 ± 8.2 31.8 ± 7.3 30.5 ± 9.0 32.3 ± 8.5 0.142
RV (mm) 23.6 ± 5.4 22.0 ± 5.0 24.1 ± 5.6 24.5 ± 5.5 24.0 ± 5.4 <0.001
LA (mm) 43.9 ± 7.7 43.1 ± 7.9 45.8 ± 8.4 46.6 ± 8.9 43.7 ± 7.5 0.002
PASP (>40 mmHg), n (%) 203(18.1) 35(15.8) 24(29.3) 15(22.4) 129(17.2) 0.031
Medicine during admission
Diuretics, n (%) 1059(94.6) 205(92.8) 76(92.7) 63(94.0) 715(95.5) 0.362
ACEI/ARB, n (%) 951(85.0) 182(82.4) 70(85.4) 54(80.6) 645(86.1) 0.396
Beta-blockers, n (%) 1017(90.9) 195(88.2) 69(84.1) 56(83.6) 697(93.1) 0.002
Digoxin, n (%) 903(80.7) 168(76.0) 66(80.5) 59(88.1) 610(81.4) 0.127
Aspirin/anticoagulants n (%) 721(64.4) 131(59.3) 52(63.4) 34(50.7) 504(67.3) 0.013
Spironolactone, n (%) 1019(91.1) 191(86.4) 73(89.0) 57(85.1) 698(93.2) 0.004
aData are expressed as the means ± SDs or medians (interquartile ranges) or as percentages, P values from an ANOVA or chi-square test for all four groups.
Bold data indicated P <0.05
bThirty-four patients lacked echocardiography data; 47 patients lacked data on PASP; 341 patients lacked NT-pro-BNP levels; 52 patients lacked fasting blood glucose
levels; 46 patients lacked creatinine and BUN levels; 51 patients lacked CK-MB levels; and 89 patients lacked triglyceride and total cholesterol levels
cAbbreviations: NYHA New York Heart Association, SBP systolic blood pressure, DBP diastolic blood pressure, TB total bilirubin, DB direct bilirubin, BUN blood urea
nitrogen, CK-MB heart-type creatine kinase isoenzyme, PASP pulmonary artery systolic pressure, NT-pro-BNP N-terminal fragment pro-brain natriuretic peptide, LV
left ventricle, LA left atrium, LVEF left ventricular ejection fraction, ACEI angiotension-converting enzyme inhibitor, ARB angiotension receptor blocker
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Fig. 3 Kaplan-Meier survival curves for patients with DCM: patients with LBBB, RBBB, IVCD and narrow QRS (log-rank χ2 = 51.564, P < 0.001).
Abbreviations: DCM, dilated cardiomyopathy; VCB, Ventricular conduction block; LBBB, left bundle branch block; RBBB, right bundle branch block;
IVCD, intraventricular conduction delay
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patients had LBBB than RBBB or IVCD. Patients with
LBBB had longer QRS durations, larger LV diameters
and lower LVEF values than those with RBBB. However,
patients with RBBB had more frequent of PASP ≥
40 mmHg, along with larger RV diameters, than those
with LBBB.
One of the reasons for a worse prognosis in patients with
RBBB may be that they have an elevated pulmonary pres-
sure compared with those with LBBB or a narrow QRS.
Acquired RBBB is often associated with PH and right-sided
cardiac failure, and PH complicated by heart failure is gen-
erally considered to be an indicator of a poor prognosis
[11, 15]. In addition, right ventricular dysfunction has an
additive predictive value in patients with left ventricular
systolic dysfunction [16]. Furthermore, RBBB may be a
marker not only of right ventricular dysfunction but also of
severe intraventricular desynchronization of both ventri-
cles. Recently, Fantoni et al. [17] reported that patients
with RBBB had larger right ventricle electrical conduction
delays compared with patients with LBBB using electro-
magnetic, catheter-based, 3-dimensional mapping. In the
present study, compared with LBBB, patients with RBBB
had more frequent of PASP ≥ 40 mmHg, larger RV diame-
ters and higher all-cause mortality rates during follow-up.
Very limited data exists on patients with IVCD. Patients
with myocardial infarction with IVCD had significantlygreater interventricular asynchronies and higher BNP
levels than post-myocardial infarction patients without
IVCD [18]. In the Multicenter Unsustained Tachycardia
Trial (MUSTT), patients with LBBB or IVCD had lower
ejection fractions and a higher prevalence of congestive
heart failure than those without these abnormalities. The
presence of IVCD was associated with a 1.5-fold increased
risk of cardiac arrest and total mortality in the patients
treated with cardiac resynchronization therapy (CRT) [8].
In another study on heart failure with CRT, the all-cause
mortality was also higher in patients with IVCD than
LBBB or RBBB; the worst prognosis was seen in patients
with IVCD [19]. The reason for the higher mortality rates
in patients with IVCD is unclear, and further research is
needed to confirm the role of IVCD in DCM.
The present study has several limitations. Like all
hospital-based cohorts, this is a selected population of
patients who have been referred for treatment. As with
many studies of chronic diseases, the time of disease on-
set is not precisely known, and there may be variations
in the length of the preclinical phase that influences the
relationship between IVCD, PH and death. Because the
N-terminal pro-brain natriuretic peptide (NT-pro-BNP)
test was not commonly used until the later years of this
study and was missing in 341 patients, we excluded NT-
pro-BNP from the multivariate Cox analysis to avoid po-
tential confounding variables in the statistical analyses.
Table 2 Cox-regression of all-cause mortality in patients with DCM
Variable Univariate analysis Multivariate analysis
HR 95 % CI P-value HR 95 % CI P-value
Age 1.012 1.003–1.021 0.007 1.007 0.997–1.018 0.175
Gender 1.154 0.883–1.507 0.294 1.255 0.894–1.761 0.189
Essential hypertension 0.706 0.524–0.951 0.022 0.810 0.579–1.134 0.220
Atrial fibrillation 1.317 1.004–1.728 0.047 1.247 0.909–1.710 0.172
NYHA functional classes 1.619 1.376–1.905 <0.001 1.248 1.038–1.499 0.018
Disease duration 1.027 1.011–1.044 0.001 1.015 0.996–1.033 0.121
Smoker 0.973 0.850–1.114 0.691 0.972 0.819–1.154 0.746
Drinker 0.893 0.766–1.040 0.146 0.913 0.756–1.103 0.346
Heart rate 1.002 0.995–1.009 0.604 1.004 0.996–1.013 0.311
Systolic blood pressure 0.982 0.975–0.989 <0.001 0.992 0.981–1.003 0.148
Diastolic blood pressure 0.979 0.969–0.989 <0.001 0.989 0.974–1.004 0.136
Left ventricle 1.039 1.027–1.053 <0.001 1.016 0.998–1.016 0.078
Left atrium 1.055 1.040–1.071 <0.001 1.041 1.022–1.060 <0.001
LVEF 0.965 0.951–0.980 <0.001 0.984 0.966–1.003 0.093
LBBB 1.408 1.043–1.900 0.025 1.197 0.839–1.706 0.321
RBBB 2.091 1.387–3.154 <0.001 2.553 1.665–3.913 <0.001
IVCD 3.488 2.376–5.122 <0.001 3.726 2.417–5.745 <0.001
PASP≥ 40 mmHg 1.992 1.529–2.596 <0.001 1.403 1.040–1.893 0.027
Note: The variables analyzed in the multivariate Cox mode included age, gender, the history of essential hypertension and atrial fibrillation, drinking and smoking
status, disease duration, NYHA functional classes, systolic blood pressure, diastolic blood pressure, heart rate, left ventricle, right ventricle, left atrium diameter,
LVEF, LBBB, RBBB, IVCD and PASP ≥ 40 mmHg. Bold data indicated P <0.05
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be free of coronary artery disease. In practice, however,
coronary arteriography is not routinely performed in all
patients with congestive heart failure. Because retro-
spective studies cannot control the conditions under
which patients are recruited or investigated, aside the
patients who were once undertaken coronary artery
angiography, coronary CT scan or cardiac radionuclide
imaging in the other hospitals, there were only 334
patients undertaken coronary artery angiography and 80
patients with positive results in the present study. In
addition, to exclude the confusion with ventricular
hypertrophy, we defined patients with VCB as QRS
duration more than 120 ms. Finally, the patients who
creceived ICDs (implantable cardiac defibrillators) or
CRTs were not included, and the use of spironolactone
and digoxin was higher in the present study.Conclusions
The present study indicated that RBBB and IVCD at
admission were independent predictors of all-cause
mortality in patients with DCM.
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